180 related articles for article (PubMed ID: 29271399)
1. Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.
Choi KH; Lee SR; Hong YK; Park DS
Asian J Androl; 2018; 20(3):270-275. PubMed ID: 29271399
[TBL] [Abstract][Full Text] [Related]
2. Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years.
Iversen P; McLeod DG; See WA; Morris T; Armstrong J; Wirth MP;
BJU Int; 2010 Apr; 105(8):1074-81. PubMed ID: 22129214
[TBL] [Abstract][Full Text] [Related]
3. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
Klotz L; Drachenberg D; Singal R; Aprikian A; Fradet Y; Kebabdjian M; Zarenda M; Chin J
Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
[TBL] [Abstract][Full Text] [Related]
4. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
5. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy Plus GnRH Analogue
Buwenge M; Deodato F; Macchia G; Siepe G; Zhao X; Valicenti RK; Cilla S; Alitto AR; Ntreta M; Bisello S; Mantini G; Valentini V; Morganti AG; Cammelli S
Anticancer Res; 2019 Nov; 39(11):6373-6378. PubMed ID: 31704870
[TBL] [Abstract][Full Text] [Related]
7. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
8. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.
Pisansky TM; Hunt D; Gomella LG; Amin MB; Balogh AG; Chinn DM; Seider MJ; Duclos M; Rosenthal SA; Bauman GS; Gore EM; Rotman MZ; Lukka HR; Shipley WU; Dignam JJ; Sandler HM
J Clin Oncol; 2015 Feb; 33(4):332-9. PubMed ID: 25534388
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
10. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
Matsumoto K; Hagiwara M; Hayakawa N; Tanaka N; Ito Y; Maeda T; Ninomiya A; Nagata H; Nakamura S
Asian Pac J Cancer Prev; 2014; 15(8):3645-9. PubMed ID: 24870772
[TBL] [Abstract][Full Text] [Related]
11. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
12. [Management of gynecomastia induced by bicalutamide].
Haddad E
Ann Urol (Paris); 2006 Dec; 40 Suppl 2():S49-52. PubMed ID: 17361921
[TBL] [Abstract][Full Text] [Related]
13. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
14. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade.
Yokomizo Y; Kawahara T; Miyoshi Y; Otani M; Yamanaka S; Teranishi J; Noguchi K; Yao M; Uemura H
Biomed Res Int; 2016; 2016():4083183. PubMed ID: 27493956
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II trial of weekly bicalutamide in men with elevated prostate-specific antigen and negative prostate biopsies.
Zanardi S; Puntoni M; Maffezzini M; Bandelloni R; Mori M; Argusti A; Campodonico F; Turbino L; Branchi D; Montironi R; Decensi A
Cancer Prev Res (Phila); 2009 Apr; 2(4):377-84. PubMed ID: 19336728
[TBL] [Abstract][Full Text] [Related]
17. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
Narita S; Tsuchiya N; Kumazawa T; Maita S; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Nanjyo H; Habuchi T
World J Surg Oncol; 2012 Jan; 10():1. PubMed ID: 22214417
[TBL] [Abstract][Full Text] [Related]
18. Impact of Positive Surgical Margins after Radical Prostatectomy on Disease Progression and Adjuvant Treatment in Pathologically Localized Prostate Cancer.
Tomasković I; Milicić V; Tomić M; Ruzić B; Ulamec M
Coll Antropol; 2015 Sep; 39(3):697-700. PubMed ID: 26898068
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer tissue is masked by bicalutamide: a case report.
Ellinger J; Bastian PJ; Biermann K; Schmidt ME; Textor J; Bollmann D; Zhou H; Müller SC
Eur J Med Res; 2007 May; 12(5):212-5. PubMed ID: 17513193
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.
Corn PG; Song DY; Heath E; Maier J; Meyn R; Kuban D; DePetrillo TA; Mathew P
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):540-5. PubMed ID: 23541810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]